Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SOBI North America Is Shopping For Growth

Executive Summary

Affiliate of the Swedish rare disease specialist has a goal to build the North American business to account for 50% of global sales, an effort that will involve organic growth and M&A.

You may also be interested in...



Sobi On The Look-Out For Licensing, M&A Opportunities

Swedish Orphan Biovitrum AB may be in a launch phase with first sales of its long-acting hemophilia products in Europe, but the company is already looking ahead to use its growing commercial capabilities for other products.

Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More

“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.

Commercial Fate Of Sarepta’s DMD Gene Therapy Remains Tied To EMBARK

The company guided investors to expect a narrow initial label under a US FDA accelerated approval for SRP-9001, with expansion possible based on EMBARK.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC097723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel